此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

研究能量平衡改变对慢性淋巴细胞白血病健康反应的作用 (HIT-CLL)

2026年11月9日 更新者:David Bartlett、University of Surrey

This randomised control clinical trial aims to investigate the effects of exercise training and diet on physical and functional fitness and immunological and metabolic changes in adults with chronic lymphocytic leukaemia. Investigators will randomise participants to either 12 weeks of supervised/semi-supervised exercise only, exercise + nutritional guidance, or no exercise.

研究概览

详细说明

This study aims to perform a randomised control trial of exercise or exercise plus nutritional guidance on the physiological and immunological health of adults diagnosed with chronic lymphocytic leukaemia (CLL). Recruited participants will be randomised to either 12 weeks of an exercise-only program, an exercise-plus nutritional guidance program or a no-exercise control group. Fasting blood samples collected at Baseline and 12 weeks will measure absolute CLL cell counts, immune function, and inflammatory and metabolic biomarkers. A series of physical fitness assessments will be assessed at baseline and 12 weeks to determine physiologic reserve and resilience against external stressors. Additionally, participants will be asked to return 12 weeks after completing the intervention to assess the legacy effects of the intervention on the same physiological and blood-based biomarkers of health.

研究类型

介入性

注册 (估计的)

132

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Guildford、英国、GU2 7WG
        • University of Surrey

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Confirmed diagnosis of CLL (including small lymphocytic leukaemia) as per the International Workshop on CLL Guidelines.
  • Male or female ≥ 18 years of age
  • Able to walk on a treadmill or cycle on an ergometer
  • Pass the Physical Activity Readiness Questionnaires (PAR-Q and PAR-Q+)

Exclusion Criteria:

  • Corticosteroid therapy initiated less than 7 days before study entry. Prednisone 10mg or less or equivalent is allowed. Topical or inhaled corticosteroids are permitted.
  • Secondary malignancy within 3 years of study enrollment requiring intervention except for adequately treated basal, squamous cell carcinoma or non-melanomatous skin cancer, carcinoma in situ of the cervix, superficial bladder cancer not treated with intravesical chemotherapy or BCG within 6 months, localised prostate cancer and PSA stable.
  • Absolute contraindications to exercise: Recent (<6 months) acute cardiac event unstable angina, uncontrolled dysrhythmias causing symptoms or hemodynamic compromise, symptomatic aortic stenosis, uncontrolled symptomatic heart failure, acute pulmonary embolus, acute myocarditis or pericarditis, suspected or known dissecting aneurism and acute systemic infection.
  • Significant orthopaedic limitations, musculoskeletal disease and/or injury. Due to the nature of the study, persons with known joint, muscle or other orthopaedic limitations that restrict physical activity may be excluded.
  • Type I diabetes mellitus or uncontrolled Type II diabetes mellitus, or chronic obstructive pulmonary disease
  • Uncontrolled blood pressure (≥180/90) at rest
  • Known concurrent HIV, Hepatitis B or Hepatitis C
  • Unable to comply with other study requirements

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:HIT Group

Exercise Only

  • 3 sessions per week
  • Aerobic + Resistance Exercises

Exercise training only

实验性的:EXE+ Group

Exercise + Nutritional Guidance

  • 3 sessions per week
  • Aerobic + Resistance Exercises
  • Dietary assessment at baseline and during with guidance on eating a healthy diet provided

Exercise Training + Nutritional Guidance

无干预:Control Group

Control group will receive no exercise or nutritional guidance

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change from baseline in absolute number of CD19+/CD5+ CLL cells at week 12
大体时间:Baseline and 12 weeks

A blood sample will be taken and assessed for CD19+/CD5+ CLL frequency using flow cytometry and total lymphocyte counts to determine the absolute number of CLL cells in x10^9/L

Baseline and 12 weeks
Change from baseline in cardiorespiratory fitness (CRF: VO2peak) at week 12
大体时间:Baseline and 12 weeks

Cardiopulmonary exercise testing will be conducted to assess changes in fitness

Baseline and 12 weeks

次要结果测量

结果测量
措施说明
大体时间
Frailty
大体时间:Baseline and 12 weeks

Frailty will be determined by a series of validated physical function tests that provide a score of 0-1(Robust), 2 (Pre-Frail), 3-5 (Frail)

Baseline and 12 weeks
Muscle Strength and Endurance
大体时间:Baseline and 12 weeks

Estimated one repetition maximum and repetitions to failure using machine-based weights

Baseline and 12 weeks
Muscle Health
大体时间:Baseline and 12 weeks

Ultrasound and near-infrared spectroscopy assessment of muscle fuel usage

Baseline and 12 weeks
Change in Quality of Life using the EORCT-QLQ-C30
大体时间:Baseline and 12 weeks

Quality of life will be determined by the EORCT-QLQ-C30 questionnaire

Baseline and 12 weeks
Change in muscle oxygen metabolism during a single bout of exercise
大体时间:Baseline and 12 weeks

Measurement of muscle oxygenation via near infrared spectroscopy during a single session of acute exercise

Baseline and 12 weeks
Change in B-CLL Cell Function
大体时间:Baseline and 12 weeks

Measurement of in vitro B-CLL cell proliferation by flow cytometry

Baseline and 12 weeks
Change in systemic and cellular bioenergetics
大体时间:Baseline and 12 weeks

Measurement of in vitro immune cell fuel utilisation by high resolution respirometry and mass spectrometry

Baseline and 12 weeks

其他结果措施

结果测量
措施说明
大体时间
Legacy Effect of Intervention on change in cardiorespiratory fitness (VO2peak) as measured by a cardiopulmonary exercise test
大体时间:12 weeks to 24 weeks

Reassessment of CRF following 12 weeks of unguided exercise training

12 weeks to 24 weeks
Legacy Effect of Intervention on absolute number of CD19+/CD5+ CLL cells
大体时间:12 weeks to 24 weeks

Reassessment of absolute number of CD19+/CD5+ CLL cells following 12 weeks of unguided exercise training

12 weeks to 24 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:David Bartlett, PhD、University of Surrey

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年10月14日

初级完成 (实际的)

2025年8月1日

研究完成 (估计的)

2030年8月1日

研究注册日期

首次提交

2024年2月9日

首先提交符合 QC 标准的

2024年4月22日

首次发布 (实际的)

2024年4月23日

研究记录更新

最后更新发布 (实际的)

2026年11月10日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅